Real-life study on the efficacy and tolerance of a preservative-free surfactant-free latanoprost eyedrop in glaucoma patients

Abstract

Purpose : It is well known that treatment intolerance leads to compliance issues, and consequently to a lack of efficacy, which is a major concern in chronic diseases such as glaucoma. We designed a retrospective, multicenter, real-life observational study to evaluate the efficacy and tolerance of the only preservative-free surfactant-free latanoprost eyedrop (PF SF LAT) available on the European market.

Methods : Inclusion criteria were: patients suffering from open angle glaucoma or ocular hypertension and treated by the PF SF LAT as a monotherapy for at least 3 months (t3+). Exclusion criteria were: secondary acquired glaucoma, ocular surgery during the follow up after treatment initiation. Data collected were: demographic data, detailed medical and treatment history, intra-ocular pressure (IOP) at the initiation (t0) of PF SF LAT therapy, and at the last available time point after continuous treatment (t3+), reason for the switch to PF SF LAT if known, systemic and ocular tolerance at t0 and t3+, and investigator opinion about the PF SF LAT treatment. Descriptive analyses were performed (mean (m), percentage (%), mean change (Δ)).

Results : Based on inclusion and exclusion criteria, 107 patient dossiers from 11 Belgian centers were evaluated. We identified 66 naïve (N) and 40 non-naïve (NN) patients at PF SF LAT initiation (1 patient could not be classified). The IOP lowering effect was verified on the overall population (mIOP_t0=20.4 mmHg, mIOP_t3+=15.8 mmHg, ΔIOP=-4.6 mmHg), on N patients (mIOP_t0=21.7 mmHg, mIOP_t3+=15.6 mmHg, ΔIOP=-6.1 mmHg; -28.1%) and on NN patients (mIOP_t0=18.4 mmHg, mIOP_t3+=16.0 mmHg, ΔIOP=-2.3 mmHg). Reason for switching to PF SF LAT for NN patients were mainly due to poor tolerance (60.0%) and poor IOP control with prior treatment (27.5%). After switching to PF SF LAT, all reported signs and symptoms improved (12.1% of side effects at t3+ vs 31.1% at t0). In 22 patients who had poor tolerance to previous treatment, 82.6% improved after switching to PF SF LAT at t3+. The majority of investigators were satisfied about PF SF LAT tolerance (98.1%) and effectiveness (83.2%).

Conclusions : PF SF LAT is a safe and efficient treatment for glaucoma patients. By decreasing IOP and improving ocular tolerance, it can help achieving a better adherence to treatment and a better disease control, which are major concerns in chronic diseases such as glaucoma.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.